secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-070906
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi presents in vivo CNS gene editing data at ASGCT; CAST integration efficiency improved >50x
--------------------------------------------------------------------------------

- Type II nuclease MG21-1 in single AAV achieved 69% protein knockdown in mouse motor cortex and 82% in brain via systemic delivery.
- Ultra-compact Type V nuclease MG119-28 (488 aa) achieved 64% target protein knockdown and up to 52% editing efficiency in mouse CNS.
- Type V-K CAST system engineered for >50x improvement in large gene integration efficiency vs. natural system in mammalian cells.
- In vitro, MG119-28 restored dystrophin levels >50% in DMD myocytes and achieved complete gene disruption in K562 cells.
- Platform aims to enable extrahepatic in vivo gene editing for neurological and neuromuscular disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025070906/0000950170-25-070906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025070906/mgx-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer